/DRTS
DRTS Stock - Alpha Tau Medical Ltd.
Healthcare|BiotechnologyNASDAQ
$5.07+1.20%
+$0.06 (+1.20%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.99
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+77.5%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DRTS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.02 – $5.12
TARGET (TP)$9.00
STOP LOSS$4.66
RISK/REWARD1:9.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.07
52W High$5.21
52W Low$2.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,102,000 | $-1,074,000 | $-979,000 | $-776,000 | $-86,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-36,042,000 | $35.68M | $-32,136,000 | $-13,790,000 | $-9,244,000 |
| Net Income | $-31,750,000 | $-29,157,000 | $-33,762,000 | $-27,271,000 | $-8,882,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.45 | $-0.42 | $-0.53 | $-0.67 | $-0.22 |
Company Overview
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$14
Average Target
↑ 176.1% Upside
Now
$8
Low
$14
Average
$20
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2023 | Citigroup | Initiation | Buy | $8 |
| April 24th 2023 | H.C. Wainwright | Initiation | Buy | $9 |
| April 14th 2022 | Cantor Fitzgerald | Initiation | Overweight | $20 |
| April 8th 2022 | Piper Sandler | Initiation | Overweight | $19 |
Earnings History & Surprises
DRTSBeat Rate
64%
Last 14 quarters
Avg Surprise
-13.7%
EPS vs Estimate
Beats / Misses
9/4
1 met exactly
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q4 23
+41.7%
$-0.07vs$-0.12
Q1 24
+15.4%
$-0.11vs$-0.13
Q2 24
+15.4%
$-0.11vs$-0.13
Q3 24
+15.4%
$-0.11vs$-0.13
Q1 25
0.0%
$-0.13vs$-0.13
Q2 25
+14.3%
$-0.12vs$-0.14
Q3 25
-8.3%
$-0.13vs$-0.12
Q4 25
-16.7%
$-0.14vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 11, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 20, 2025 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q2 2025 | May 19, 2025 | $-0.14 | $-0.12 | +14.3% | ✓ BEAT |
Q1 2025 | Mar 12, 2025 | $-0.13 | $-0.13 | 0.0% | = MET |
Q4 2024 | Nov 21, 2024 | $-0.13 | — | — | — |
Q3 2024 | Aug 14, 2024 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q2 2024 | May 20, 2024 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q4 2023 | Nov 16, 2023 | $-0.12 | $-0.07 | +41.7% | ✓ BEAT |
Q3 2023 | Aug 28, 2023 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q2 2023 | May 23, 2023 | $-0.09 | $-0.12 | -33.3% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.12 | $-0.04 | +66.7% | ✓ BEAT |
Q4 2022 | Nov 22, 2022 | $-0.10 | $-0.04 | +60.0% | ✓ BEAT |
Q3 2022 | Aug 25, 2022 | $-0.10 | $-0.03 | +70.0% | ✓ BEAT |
Q2 2022 | May 26, 2022 | $-0.10 | $-0.54 | -440.0% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | — | $-0.08 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.07 | — | — |
Q3 2021 | Aug 17, 2021 | — | $-0.10 | — | — |
Q2 2021 | May 29, 2021 | — | $-0.17 | — | — |
Latest News
Citigroup Maintains Buy on Alpha Tau Medical, Lowers Price Target to $7
➖ NeutralBenzinga•Dec 10, 2025, 07:15 PM•Also:
Alpha Tau Medical shares are trading higher after the company announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme using the Alpha DaRT technology.
📈 PositiveBenzinga•Dec 9, 2025, 05:43 PM
Alpha Tau Medical Announces First Patient Treated In Pilot Study For Treatment Of Patients With Recurrent Glioblastoma Multiforme Using Alpha DaRT Technology
📈 PositiveBenzinga•Dec 9, 2025, 02:05 PM
Alpha Tau Medical Says FDA Approves IDE Application To Initiate Pilot Study For Treatment Of Patients With Locally Recurrent Prostate Cancer Using Alpha DaRT Technology
📈 PositiveBenzinga•Dec 2, 2025, 02:02 PM
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
📈 PositiveBenzinga•Nov 24, 2025, 12:34 PM
Alpha Tau Medical Q3 EPS $(0.14) Misses $(0.12) Estimate
📉 NegativeBenzinga•Nov 20, 2025, 09:19 PM
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
📈 PositiveBenzinga•Oct 22, 2025, 02:40 PM
Alpha Tau Receives Radioactive Material License For New Hampshire Manufacturing Facility
📈 PositiveBenzinga•Oct 21, 2025, 12:32 PM
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
📈 PositiveBenzinga•Sep 3, 2025, 10:58 AM
Frequently Asked Questions about DRTS
What is DRTS's current stock price?
Alpha Tau Medical Ltd. (DRTS) is currently trading at $5.07 per share. The stock has moved +1.20% today.
What is the analyst price target for DRTS?
The average analyst price target for DRTS is $9.00, based on 1 analyst.
What sector is Alpha Tau Medical Ltd. in?
Alpha Tau Medical Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DRTS's market cap?
Alpha Tau Medical Ltd. has a market capitalization of $0.43 billion, making it a small-cap company.
Does DRTS pay dividends?
No, Alpha Tau Medical Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
CADL
Candel Therapeutics, Inc.
$5.57
Mkt Cap: $0.3B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
DMAC
DiaMedica Therapeutics Inc.
$8.48
Mkt Cap: $0.4B
GNLX
Genelux Corporation
$4.20
Mkt Cap: $0.2B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
Explore stocks similar to DRTS for comparison